Aprea Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Aprea Therapeutics, Inc. (APRE) reported Earnings Per Share, Basic and Diluted of -$0.48 per share for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-08-12
- Aprea Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.48.
- Aprea Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.46.
- Aprea Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$0.73.
- Aprea Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.58.
- Aprea Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$2.53.
- Aprea Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$4.67.
- Aprea Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2018 was -$13.45.
- Aprea Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2017 was -$13.17.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-06-30 | -$0.48 10-Q · filed 2021-08-12 | -$0.94 10-Q · filed 2021-08-12 | -$1.67 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$2.25 derived: net income ÷ weighted average shares · filed 2023-03-30 |
| 2021-03-31 | -$0.46 10-Q · filed 2021-05-06 | -$1.18 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$1.76 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$2.54 derived: net income ÷ weighted average shares · filed 2023-03-30 |
| 2020-12-31 | -$0.73 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$1.31 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$2.08 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$2.53 10-K · filed 2021-03-16 |
| 2020-09-30 | -$0.58 10-Q · filed 2020-11-06 | -$1.36 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.80 10-Q · filed 2020-11-06 | -$2.44 derived: net income ÷ weighted average shares · filed 2022-03-15 |
| 2020-06-30 | -$0.78 10-Q · filed 2021-08-12 | -$1.22 10-Q · filed 2021-08-12 | -$1.86 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$2.83 derived: net income ÷ weighted average shares · filed 2022-03-15 |
| 2020-03-31 | -$0.45 10-Q · filed 2021-05-06 | -$1.08 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$2.02 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$3.10 derived: net income ÷ weighted average shares · filed 2022-03-15 |
| 2019-12-31 | -$0.64 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$1.78 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$3.23 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$4.67 10-K · filed 2021-03-16 |
| 2019-09-30 | -$5.29 10-Q · filed 2020-11-06 | -$9.74 derived: net income ÷ weighted average shares · filed 2020-11-06 | -$12.72 10-Q · filed 2020-11-06 | -$16.78 derived: net income ÷ weighted average shares · filed 2021-03-16 |
| 2019-06-30 | -$4.45 10-Q · filed 2020-08-11 | -$7.43 10-Q · filed 2020-08-11 | -$11.48 derived: net income ÷ weighted average shares · filed 2021-03-16 | -$14.20 derived: net income ÷ weighted average shares · filed 2021-03-16 |
| 2019-03-31 | -$2.97 10-Q · filed 2020-05-15 | -$7.01 derived: net income ÷ weighted average shares · filed 2021-03-16 | -$9.73 derived: net income ÷ weighted average shares · filed 2021-03-16 | |
| 2018-12-31 | -$4.05 derived: net income ÷ weighted average shares · filed 2021-03-16 | -$6.77 derived: net income ÷ weighted average shares · filed 2021-03-16 | -$13.45 10-K · filed 2021-03-16 | |
| 2018-09-30 | -$2.72 10-Q · filed 2019-11-14 | -$9.40 10-Q · filed 2019-11-14 | ||
| 2017-12-31 | -$13.17 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |